<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="223404">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174421</url>
  </required_header>
  <id_info>
    <org_study_id>98-8122-011</org_study_id>
    <secondary_id>A6281219</secondary_id>
    <nct_id>NCT00174421</nct_id>
  </id_info>
  <brief_title>Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height</brief_title>
  <official_title>Genotropin in Short Children Born Small for Gestational Ag - A Long-Term Study in Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This trial evaluates whether long-term treatment with Genotropin normalizes final (adult)
      height in short children born small for gestational age
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date>August 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final height, compared to the expected familial target height</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight, body mass index at final height; adverse events and assessment of hematological and clinical chemistry</measure>
  </secondary_outcome>
  <enrollment>36</enrollment>
  <condition>Growth Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with Genotropin in different dosages</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in the 90-080 study

        Exclusion Criteria:

          -  Any severe, acute or chronic disease

          -  Any other identifiable reason for short stature
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <verification_date>May 2007</verification_date>
  <lastchanged_date>May 1, 2007</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Growth Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
